IP Library › Granted Patent US 12,611,402
Granted Patent B2
US 12,611,402 · App. 17/839,169 · Granted Apr 28, 2026

Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

Inventors: Nigel Ramsden (Cambridge, GB); David John Fox (Coventry, GB); James Andrew Huntington (Cheshire, GB); James Michael Tomlinson (Babraham, GB)
Assignee: CENTESSA PHARMACEUTICALS (UK) LIMITED
A61K31/451A61K31/4015A61K31/4709A61P1/16A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,611,402
App. No.
17/839,169
Granted
Apr 28, 2026
Kind
B2
Abstract

The invention relates to specified carboxylic acid compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α 1 -antitrypsin (A1AT) and may be used in the treatment of a disease or disorder such as α 1 -antitrypsin deficiency (A1AD or AATD).

Claims (29)

1 . A method of inducing Z A1AT secretion in a subject in need thereof, comprising administering to the subject a compound represented by the structure:

or a pharmaceutically acceptable salt of any one thereof.

2 . A method of treating α 1 -antitrypsin deficiency (AATD), in a subject in need thereof, comprising administering to the subject a compound represented by the structure:

or a pharmaceutically acceptable salt of any one thereof.

3 . The method of claim 1 , wherein the method comprises administering a mixture of enantiomers selected from (a), (b), (c), or (d):

4 . The method of claim 1 , wherein the compound is represented by:

or a pharmaceutically acceptable salt of any one thereof.

5 . The method of claim 4 , wherein the compound is represented by:

or a pharmaceutically acceptable salt of any one thereof.

6 . The method of claim 5 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 5 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 5 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

9 . The method of claim 2 , wherein the method comprises administering a mixture of enantiomers selected from (a), (b), (c), or (d):

10 . The method of claim 2 , wherein the compound is represented by:

or a pharmaceutically acceptable salt of any one thereof.

11 . The method of claim 10 , wherein the compound is represented by:

or a pharmaceutically acceptable salt of any one thereof.

12 . The method of claim 11 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

13 . The method of claim 11 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

14 . The method of claim 11 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

15 . The method of claim 2 , wherein the administering increases levels of Z A1AT in the subject.

16 . The method of claim 15 , wherein the administering does not affect the levels of wild type (M) A1AT in the subject.

17 . The method of claim 15 , wherein the administering does not affect the Siiyama variant of A1AT in the subject.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2026
From: OXFORD FINANCE LLC
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 075069/0879 →
SECURITY INTEREST Recorded Dec 31, 2024
From: CENTESSA PHARMACEUTICALS (UK) LIMITED
To: OXFORD FINANCE LLC
Reel/Frame 069708/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2023
From: Z FACTOR LIMITED
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 065294/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: RAMSDEN, NIGEL, DR.; FOX, DAVID JOHN, DR.; HUNTINGTON, JAMES ANDREW; TOMLINSON, JAMES MICHAEL, DR.
To: Z FACTOR LIMITED
Reel/Frame 061931/0427 →
Priority Claims (1)
GB 1918410 · Dec 13, 2019 · national
Continuity (2)
Continuation PCTGB2020053187 · Dec 11, 2020
Related Publication 20230089087A1 · Mar 23, 2023
References Cited (55)
US 8436013B2 · Liu et al. · 2013 [cited by applicant]
US 9084782B2 · Kwon et al. · 2015 [cited by applicant]
US 20060035884A1 · Neitzel · 2006 [cited by examiner]
US 20110065707A1 · Ackermann et al. · 2011 [cited by applicant]
US 20200361939A1 · Bandarage et al. · 2020 [cited by applicant]
US 20240197707A1 · Ramsden et al. · 2024 [cited by applicant]
EP 0520336A2 · 1992 [cited by applicant]
JP H05345753A · 1993 [cited by applicant]
JP 2007538106A · 2007 [cited by applicant]
JP 2013504544A · 2013 [cited by applicant]
WO WO2005113542A2 · 2005 [cited by applicant]
WO WO2008143633A2 · 2008 [cited by applicant]
WO WO2011029808A1 · 2011 [cited by applicant]
WO WO2011110852A1 · 2011 [cited by applicant]
WO WO2018104220A1 · 2018 [cited by applicant]
WO WO2019243841A1 · 2019 [cited by applicant]
WO WO2020081257A1 · 2020 [cited by applicant]
WO WO2021116703A1 · 2021 [cited by applicant]
WO WO2022263816A1 · 2022 [cited by applicant]
Elkins et al., “Variability in High-throughput Ion-Channel Screening Data and Consequences for Cardiac Safety Assessment,” Journal of Pharmacological and Toxicological Methods 68:112-122 (2013). [cited by applicant]
Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Department of Health and Human Services—FDA, Jul. 2005, Retrieved from the I… [cited by applicant]
PCT/GB2022/051502 International Search Report and Written Opinion dated Aug. 17, 2022. [cited by applicant]
Weaver et al., “Cytochrome P450 Inhibition Using Recombinant Proteins and Mass Spectrometry/multiple Reaction Monitoring Technology in a Cassette Incubation,” Drug Metabolism and Disposition 31(7):955-966 (2003). [cited by applicant]
Chemical Abstracts Service. CAS Registry: 1786870-80-1. STN Entry Date Jun. 23, 2015. [cited by applicant]
Chemical Abstracts Service. CAS Registry: 2649795-64-0. STN Entry Date Jul. 6, 2021. [cited by applicant]
Chemical Abstracts Service. CAS Registry: 727983-32-6. STN Entry Date Aug. 18, 2004. [cited by applicant]
Chemical Abstracts Service. CAS Registry: 891392-15-7. STN Entry Date Jul. 10, 2006. [cited by applicant]
Berthelier et al. Discovery of an Inhibitor of Z-Alpha1 Antitrypsin Polymerization. PLoS One 10(5):e0126256 (May 11, 2015). [cited by applicant]
Bouchecareilh et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. J Biol Chem 287(45):38265-38278 (2012). [cited by applicant]
Burrows et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. PN… [cited by applicant]
Carlson et al. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J. Clin Invest 83:1183-90 (1989). [cited by applicant]
Certified GB1918410.0, filed Dec. 13, 2019. [cited by applicant]
Chang et al. Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization. J. Cell. Mol. Med. 13(8B):2304-2316 (2009). [cited by applicant]
Corral et al. Exploiting the Evolutionary Relationship between Malarial Parasites and Plants to Develop New Herbicides. Angew Chem Int Ed Engl 56(33):9881-9885 (2017). [cited by applicant]
Database accession No. 1394768-24-1, Chemical Abstracts Service (Sep. 18, 2012). [cited by applicant]
Database accession No. 1786658-64-7, Chemical Abstracts Service (Jun. 23, 2015). [cited by applicant]
Database accession No. 1786746-43-7, Chemical Abstracts Service (Jun. 23, 2015). [cited by applicant]
Database accession No. 1787438-88-3, Chemical Abstracts Service (Jun. 24, 2015). [cited by applicant]
Database accession No. 1840546-43-1, Chemical Abstracts Service (Jan. 3, 2016). [cited by applicant]
Database accession No. 630049-57-9, Chemical Abstracts Service (Dec. 23, 2003). [cited by applicant]
Database accession No. 727717-69-3, Chemical Abstracts Service (Aug. 17, 2004). [cited by applicant]
Database accession No. 891392-68-0, Chemical Abstracts Service (Jul. 10, 2006). [cited by applicant]
Dycaico et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. Science 242:1409-12 (1988). [cited by applicant]
Elliott et al. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Science 9:1274-1281 (2000). [cited by applicant]
GB1918410.0 Search Report dated Jun. 10, 2020. [cited by applicant]
Gould et al. Salt Selection for Basic Drugs. Int J. Pharm. 33:201-217 (1986). [cited by applicant]
Huntington. How and why the Z variant of a1-antitrypson polymerises, and what can be done about it. 7th International Symposium on Serpin Biology, Structure and Function (Apr. 1, 2014). [cited by applicant]
Knaupp et al. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation. J. Mol. Biol. 396:375-383 (2010). [cited by applicant]
Mallya et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 50(22):5357-5363 (2007). [cited by applicant]
Parfrey et al. Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease. J. Biol. Chem. 278(35):33060-33066 (2003). [cited by applicant]
PCT/GB2020/053187 International Search Report and Written Opinion dated Feb. 1, 2021. [cited by applicant]
Reddy et al. Synthesis and Antimicrobial screening of Some New Piperidine Derivatives. Journal of Applicable Chemistry 2(6):1501-1508 (2013). [cited by applicant]
Seyama et al. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 266:12627-32 (1991). [cited by applicant]
Chemical Abstracts Service. CAS Registry: 1384659-27-1. 3-Pyrrolidinecarboxylic acid, 1-[[2-(trifluoromethyl)phenyl]sulfonyl]−,(3S)−. STN Entry Date Jul. 27, 2012. [cited by applicant]
Chemical Abstracts Service. CAS Registry: 1840546-43-1; Component RN 1384659-27-1. 3-Pyrrolidinecarboxylic acid, 1-[[2-(trifluoromethyl)phenyl]sulfonyl]−, hydrochloride (1:1). STN Entry Date Jan. 3, 2016. [cited by applicant]